Rare Disease Genetic Testing Market to Grow at 13.1% CAGR

Introduction

The Global Rare Disease Genetic Testing Market is projected to expand significantly, from USD 918.94 million in 2023 to USD 3,051.6 million by 2032, growing at a CAGR of 13.1%. This growth is fueled by technological advancements in genomic sequencing technologies, including next-generation sequencing (NGS), which enhances the precision in identifying rare genetic mutations. The integration of artificial intelligence (AI) and big data further accelerates this progress by improving the analysis and interpretation of complex genetic data, thereby enhancing diagnostic accuracy.

Awareness and advocacy are pivotal in advancing the rare disease genetic testing sector. Increased public and professional awareness, driven by initiatives such as Rare Disease Day and enhanced funding for genetic research, play crucial roles in the sector’s growth. These efforts are supported by collaborative research among institutions, healthcare providers, and technology firms, exemplified by programs like the Mayo Clinic’s Center for Individualized Medicine, which integrates genomics into clinical practice.

Regulatory and policy support also significantly impacts the expansion of genetic testing for rare diseases. Supportive government policies and regulations facilitate research advancements and the clinical adoption of genetic tests, improving patient outcomes. Ethical considerations, including consent and privacy in genetic testing, are increasingly addressed, ensuring patient trust and wider acceptance of these technologies.

Recent industry developments further underscore the sector’s growth. In August 2024, Quest Diagnostics acquired LifeLabs from OMERS for about USD $1 billion, aiming to enhance diagnostic services and integrate LifeLabs’ capabilities, particularly in North America. This strategic acquisition is anticipated to generate approximately USD $710 million annually in revenues, bolstering healthcare and diagnostic services across the region.

In April 2023, Centogene introduced the NEW CentoGenome, a comprehensive Whole Genome Sequencing (WGS) test designed to improve the diagnostic process for rare and neurodegenerative diseases. This advanced test includes the detection of Copy Number Variations and complex disease-causing variants, which enhances diagnostic accuracy and could hasten the path to effective treatments. This launch highlights the continuous innovation within the genetic testing field, promising improved outcomes for patients with rare genetic disorders.

Key Takeaways

• The genetic testing market is projected to grow from USD 918.94 million in 2023 to USD 3,051.6 million by 2032, with a CAGR of 13.1%.
• Growing global populations necessitate genetic testing for rare diseases, which is driving market expansion.
• Enhanced accuracy from technological advancements in genetic testing is increasing its usage for diagnosing rare diseases.
• Continuous product innovations are stimulating growth in the genetic testing market.
• The high costs associated with genetic testing pose affordability challenges, particularly in low- and middle-income regions.
• The market for genetic testing for endocrine disorders is rapidly expanding, expected to grow at a 21.0% CAGR.
• Next-Generation Sequencing (NGS) technology leads the technology segment, generating over 35.22% of market revenue.
• Research laboratories and Contract Research Organizations (CROs) held over 47% of the market share among end-users in 2022.
• Diagnostic laboratories are anticipated to grow the fastest, with a projected CAGR of 16.1% throughout the forecast period.
• Asia Pacific is forecasted to experience the highest regional growth rate at an 18.1% CAGR, driven by increased diagnostic awareness and supportive government policies.

Rare Disease Genetic Testing Statistics

Overview of Rare Disease Genetic Testing

• A rare condition affects fewer than 1 in 2,000 people in the UK, qualifying any disease affecting fewer than 200,000 in the U.S. as rare.
• There are approximately 7,000 known rare diseases globally, with numbers increasing as research advances.
• Globally, around 350 million people are affected by rare diseases, which equates to about 10% of the world’s population.
• Genetic mutations are the cause of approximately 80% of rare diseases.

Impact on Children

• Roughly 70% of rare diseases manifest in childhood, frequently leading to chronic, debilitating conditions and premature death.
• Over 30% of children with a rare disease do not live past their fifth birthday.
• Early diagnosis is crucial as 7 out of 10 rare diseases predominantly affect children.

Diagnostic Challenges and Advances

• The average time to receive an accurate rare disease diagnosis is 4.8 years, involving consultations with over seven different specialists.
• Over a third of individuals with a rare disease wait more than five years for an accurate diagnosis.
• Annually, about 6,000 UK children are born with a genetic condition that remains unnamed at birth.

Genetic Testing and Research

• The 100,000 Genomes Project has diagnosed 1 in 4 people with an undiagnosed rare condition for the first time.
• As of 2018, there are 11,548 genetic diagnostic tests available, primarily postnatal, across 522 institutions mainly in Europe.
• Rapid genome sequencing, which examines all 3 billion DNA base pairs, is a crucial tool in identifying genetic abnormalities.
• Despite advancements, only 5% of rare conditions have an approved treatment, highlighting a significant therapeutic gap.

Screening and Care Coordination

• UK newborn screening currently includes 9 rare genetic conditions, with plans to expand.
• More than 20 European countries screen for more genetic conditions than the UK, most screening for over 20 conditions.
• Only 10% of UK adults with a rare condition have a care coordinator, and similarly, only 40% of children have a care plan in place.

Market Analysis and Financial Aspects

• The panel-based sequencing market holds a 14% share in genetic testing, with 55% still employing Sanger sequencing for verification.
• In the first half of 2023, Centogene’s total revenue was €24.6 million, a 15.1% increase year-over-year, driven by strong performances in both Pharma and Diagnostics segments.
• Centogene secured a $30 million investment from Lifera and about $50 million in upfront payments and milestones through a joint venture.

Genetic Testing Usage and Access

• Somatic genetics for pediatric cancers and prenatal diagnosis constitute approximately 5.24% and 5.05% of all tests, respectively.
• Less than 1% of genetic tests are used for preimplantation genetic diagnosis due to technical challenges.
• In 2023, 860 patients with suspected rare diseases were tested for genetic causes at Mayo Clinic, with 30% having their diseases identified.
• Around 15% of patients seeking a second opinion or treatment at Mayo Clinic are diagnosed with a rare disease.

Emerging Trends

• Increased Integration of AI and Digital Health Tools: The integration of artificial intelligence (AI) and digital health tools is revolutionizing genetic testing for rare diseases. AI enhances the efficiency of genetic data analysis, which speeds up the diagnostic process. This integration enables healthcare providers to develop more tailored treatment plans, adapting swiftly to individual patient needs. The utilization of these advanced technologies ensures that patients receive a faster diagnosis, and it paves the way for more personalized healthcare solutions.
• Expansion of Translational Genomics: Translational genomics is rapidly expanding, translating genetic research into practical healthcare solutions. This approach is particularly significant in developing diagnostics and novel therapies for rare genetic disorders, such as Duchenne muscular dystrophy and spinal muscular atrophy. Researchers are making strides in applying these genetic findings to real-world applications, bridging the gap between research labs and clinical settings. This progress promises to enhance patient care by turning scientific discoveries into actionable medical practices.
• Wider Use of Next-Generation Sequencing (NGS) Technologies: Next-generation sequencing (NGS) technologies are becoming more prevalent in researching rare diseases. NGS allows for the detailed analysis of genetic material, helping identify new disease-gene associations. This advancement expands diagnostic capabilities, enabling earlier and more accurate detection of genetic disorders. The increased adoption of NGS technologies underscores their potential to significantly impact the diagnosis and treatment of rare diseases, leading to more timely and effective interventions.
• Collaborative Networks and Patient Engagement: The trend towards building collaborative research networks and patient registries is enhancing the scope and depth of rare disease research. These networks facilitate extensive data sharing and cooperation among scientists and clinicians, which is crucial for advancing our understanding of rare genetic disorders. Furthermore, engaging patients directly in research helps tailor developments to their specific needs, ensuring that new treatments are effectively targeted and truly beneficial. This collaborative approach fosters a deeper connection between research activities and patient communities, driving forward the development of specialized treatments.

Use Cases

• Diagnostic Clarity and Family Screening: Genetic testing provides clear diagnoses for individuals presenting with symptoms that are not specific, which aids in determining the appropriate and most effective treatments. This testing is not only crucial for individual patients but also offers the possibility to screen family members. Identifying those at risk can lead to early interventions and preventive care measures, enhancing health outcomes and providing peace of mind for families dealing with potential hereditary conditions.
• Informing Treatment Protocols: By pinpointing the exact genetic mutations that cause a disease, genetic testing is instrumental in tailoring treatment plans. It facilitates the use of targeted therapies that directly tackle the genetic basis of the illness. Examples include gene therapy and biologically engineered treatments that are designed to correct the genetic abnormalities specifically associated with the patient’s condition, thereby enhancing treatment efficacy and patient recovery rates.
• Preventing Misdiagnosis: Genetic testing plays a pivotal role in reducing the misdiagnosis of rare diseases, which often share symptoms with more common ailments. Accurate genetic analysis helps ensure that patients receive the most appropriate treatment, avoiding the risks and costs associated with incorrect diagnoses. This is particularly important in preventing the use of treatments that are unnecessary or potentially harmful, thus safeguarding patient health.
• Supporting Drug Development and Approval: In the realm of drug development, genetic testing helps identify specific patient subgroups who are likely to benefit from new pharmacological treatments. This information is crucial for conducting effective clinical trials and expediting the U.S. Food and Drug Administration (FDA) approval process. By demonstrating drug efficacy in targeted patient populations, genetic testing facilitates the introduction of innovative therapies tailored to treat rare genetic disorders, significantly impacting the field of personalized medicine.

Conclusion

In conclusion, the Rare Disease Genetic Testing market is poised for significant growth, driven by advancements in genomic sequencing and the integration of AI. This surge is underpinned by rising awareness and robust support from regulatory bodies which facilitate the adoption of advanced diagnostic tests. Industry developments, such as strategic acquisitions and innovations in testing capabilities, highlight ongoing momentum and investment in the field. As technology evolves and collaborative efforts expand, genetic testing is becoming increasingly crucial in diagnosing and managing rare diseases, thereby improving patient outcomes and enhancing the precision of medical treatments. This evolution marks a promising shift towards more personalized and effective healthcare solutions for rare disease patients.

Discuss Your Needs With Our Analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF